Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

The Natural History of Myeloma Patients Who Relapse Early After High Dose Therapy.

Nory Holle, Ping Wu, MBBS, MSc, Charlotte Pawlyn, MD, Radovan Saso, MD, MPhil, PhD, Jennifer G. Treleaven, MD, Michael Potter, MD PhD, Mark E Ethell, MD, Bronwen E. Shaw, MD PhD, Walter M Gregory, PhD, Sandra Croockewit, MD, Gareth J. Morgan, MD PhD, Faith E. Davies, MD

Blood (2012) 120 (21): 3125.

https://doi.org/10.1182/blood.V120.21.3125.3125

Published: 2012

Journal Articles

The Introduction of Novel Agents Improves Outcomes of Young Patients with Myeloma (MM) Treated with Autologous Stem Cell Transplant (ASCT)

Radovan Saso, MD, MPhil, PhD, Kevin D Boyd, MB.BS, Kabir Mohammed, Ping Wu, Jennifer Treleaven, Faith E. Davies, MD, Gareth J Morgan, MD, PhD

Blood (2010) 116 (21): 1348.

https://doi.org/10.1182/blood.V116.21.1348.1348

Published: 2010

Journal Articles

Autologous Transplantation Is the Optimum Approach to the Management of Myeloma Patients with Extramedullary Disease at Presentation

Faith E. Davies, Ping Wu, Kevin Boyd, Radovan Saso, Michael N Potter, Mark E Ethell, Bronwen E Shaw, Jenny Treleaven, Sharon Dines, Gareth J Morgan

Blood (2008) 112 (11): 3313.

https://doi.org/10.1182/blood.V112.11.3313.3313

Published: 2008

Journal Articles

Duration of Initial Admission and Subsequent Readmission in the First 100 Days Following Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation.

Moez Dungarwalla, MRCP, Joy Brennan, Samar Kulkarni, MRCPath, Radovan Saso, PhD, Bronwen Shaw, MRCPath, Treleaven G. Jennifer, FRCPath, Dearden E. Claire, FRCPath, Morgan J. Gareth, FRCPath, Ethell E. Mark, MRCPath, Potter N. Mike, FRCPath

Blood (2007) 110 (11): 1999.

https://doi.org/10.1182/blood.V110.11.1999.1999

Published: 2007

Journal Articles

Maintenance Chemotherapy (MC) after Autotransplantation in First-Remission Acute Lymphoblastic Leukemia (ALL): Single-Center Experience of 100 Patients.

Bhawna Sirohi, Ray Powles, Jennifer Treleaven, Samar Kulkarni, Radovan Saso, Mike Potter, Mark Ethell, Gareth Morgan, Seema Singhal, Jayesh Mehta

Blood (2007) 110 (11): 2874.

https://doi.org/10.1182/blood.V110.11.2874.2874

Published: 2007

Journal Articles

Incidence of Second Malignant Neoplasms (SMN) after Haematopoetic Stem Cell Transplant.

Samar Kulkarni, MRCP, Michael Potter, MRCPath, Mark Ethell, PRCPath, Radovan Saso, PhD, Jennifer Treleaven, FRCPath, Joy Brennan, BSc, Pawel Kaczmarek, MRCP, Prashant Hiwarkar, MRCP, Pamala Kanagasabapathy, MRCP, Caroline Alvares, MRCPath, Clive Horton, PhD, Raymond Powles, FRCP, Frank Saran, FRCR, Gareth Morgan, FRCPath

Blood (2006) 108 (11): 551.

https://doi.org/10.1182/blood.V108.11.551.551

Published: 2006

Journal Articles

Lymphocyte Count on Day 56 Predicts for Reduced Risk of Infection Related Mortality Following Non-Myeloablative Allogeneic Haematopoietic Stem Cell Transplantation.

Caroline Alvares, MRCPath, Samar Kulkarni, MRCP, Pawel Kaczmarek, PhD, Radovan Saso, PhD, Helena Woods, Joy Brennan, BSc, Clive Horton, PhD, Jennifer Treleaven, FRCPath, Mark Ethell, MRCPath, Claire Dearden, MRCPath, Gareth Morgan, FRCPath, Michael Potter, FRCPath

Blood (2006) 108 (11): 5324.

https://doi.org/10.1182/blood.V108.11.5324.5324

Published: 2006

Journal Articles

Outcomes of Patients with Hematological Malignancies Admitted to Critical Care.

Girish Ravindranathan, MRCP, Vaia Grigoriadou, MRCP, Radovan Saso, MD, PhD, Shelley Dolan, MSc, PhD, Mark Ethell, MRCP, MRCPath, Michael Potter, FRCP, FRCPath, Jennifer Treleaven, FRCP, FRCPath, Gareth Morgan, FRCP, FRCPath

Blood (2006) 108 (11): 5289.

https://doi.org/10.1182/blood.V108.11.5289.5289

Published: 2006

Journal Articles

Pregnancy Outcome Following Haematopoietic Stem Cell Transplantation.

Samar Kulkarni, MRCP, Mark Ethell, MRCPath, Jennifer Treleaven, FRCPath, Radovan Saso, PhD, Joy Brennan, BsC, Pawel Kaczmarek, PhD, Caroline Alvares, MRCPATH, Clive Horton, PhD, Frank Saran, FRCR, Pamala Kanagasabapathy, MRCP, Prashant Hiwarkar, MRCP, Stella Appiah-Cubi, MRCP, Moez Dungarwala, MRCP, Raymond Powles, FRCP, Gareth Morgan, FRCPath, Michael Potter, FRCPath

Blood (2006) 108 (11): 3367.

https://doi.org/10.1182/blood.V108.11.3367.3367

Published: 2006

Journal Articles

Lenolidamide (Revlimid), in Combination with Cyclophosphamide and Dexamethasone (CRD) Is an Effective Regimen for Heavily Pre-Treated Myeloma Patients.

Gareth J. Morgan, PhD, Stephen Schey, MD, Ping Wu, M. Srikanth, MD, Karen J. Phekoo, Matthew W. Jenner, MD, Sharon Dines, Radovan Saso, MD, Faith E. Davies, MD

Blood (2006) 108 (11): 3555.

https://doi.org/10.1182/blood.V108.11.3555.3555

Published: 2006

Journal Articles

The Combination of Cyclophosphamide, Velcade and Dexamethasone (CVD) Induces High Response Rates with Minimal Toxicity Compared to Velcade Alone (V) and Velcade Plus Dexamethasone (VD).

Faith E. Davies, MD, Ping Wu, M. Srikanth, MD, Matthew W. Jenner, MD, Sharon Dines, Radovan Saso, MD, Gareth J. Morgan, PhD

Blood (2006) 108 (11): 3537.

https://doi.org/10.1182/blood.V108.11.3537.3537

Published: 2006

Journal Articles

A Comparative Analysis of Outcomes in Primary Myelodysplastic Syndrome (MDS) and Therapy-Related MDS Reveals Two Subgroups with Differing Risk Profiles: Implications for the Application of a Prognostic Classification.

Caroline Alvares, Sue Ashley, Radovan Saso, Gita Patel, Amrana Qureshi, Michael Potter, Mark Ethell, Jennifer Treleaven, Claire Dearden, Gareth Morgan

Blood (2005) 106 (11): 2532.

https://doi.org/10.1182/blood.V106.11.2532.2532

Published: 2005

Journal Articles

Responses to Induction Chemotherapy and High Dose Melphalan Can Be Incorporated within a Risk Stratification Model and Help to Identify Myeloma Patients Who May Benefit from Novel Therapies.

Caroline L. Alvares, Faith E. Davies, Clive Horton, Gita Patel, Roslin Zuha, Alex Gatt, Radovan Saso, Jennifer Treleaven, Mark Ethell, Mike Potter, Claire Dearden, Gareth J. Morgan

Blood (2004) 104 (11): 2394.

https://doi.org/10.1182/blood.V104.11.2394.2394

Published: 2004

Journal Articles

Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants

Samar Kulkarni, Ray Powles, Jennie Treleaven, Unell Riley, Seema Singhal, Clive Horton, Bhawna Sirohi, Niyati Bhagwati, Simon Meller, Radovan Saso, Jayesh Mehta

Blood (2000) 95 (12): 3683–3686.

https://doi.org/10.1182/blood.V95.12.3683

Published: 2000

NARROW

The Natural History of Myeloma Patients Who Relapse Early After High Dose Therapy.

The Introduction of Novel Agents Improves Outcomes of Young Patients with Myeloma (MM) Treated with Autologous Stem Cell Transplant (ASCT)

Autologous Transplantation Is the Optimum Approach to the Management of Myeloma Patients with Extramedullary Disease at Presentation

Duration of Initial Admission and Subsequent Readmission in the First 100 Days Following Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation.

Maintenance Chemotherapy (MC) after Autotransplantation in First-Remission Acute Lymphoblastic Leukemia (ALL): Single-Center Experience of 100 Patients.

Incidence of Second Malignant Neoplasms (SMN) after Haematopoetic Stem Cell Transplant.

Lymphocyte Count on Day 56 Predicts for Reduced Risk of Infection Related Mortality Following Non-Myeloablative Allogeneic Haematopoietic Stem Cell Transplantation.

Outcomes of Patients with Hematological Malignancies Admitted to Critical Care.

Pregnancy Outcome Following Haematopoietic Stem Cell Transplantation.

Lenolidamide (Revlimid), in Combination with Cyclophosphamide and Dexamethasone (CRD) Is an Effective Regimen for Heavily Pre-Treated Myeloma Patients.

The Combination of Cyclophosphamide, Velcade and Dexamethasone (CVD) Induces High Response Rates with Minimal Toxicity Compared to Velcade Alone (V) and Velcade Plus Dexamethasone (VD).

A Comparative Analysis of Outcomes in Primary Myelodysplastic Syndrome (MDS) and Therapy-Related MDS Reveals Two Subgroups with Differing Risk Profiles: Implications for the Application of a Prognostic Classification.

Responses to Induction Chemotherapy and High Dose Melphalan Can Be Incorporated within a Risk Stratification Model and Help to Identify Myeloma Patients Who May Benefit from Novel Therapies.

Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only